Filtered By:
Therapy: Stem Cell Therapy
Vaccination: Vaccines

This page shows you your search results in order of date.

Order by Relevance | Date

Total 108 results found since Jan 2013.

Fight Aging! Newsletter, July 10th 2023
In conclusion, the examination of the GBA can aid in understanding the etiology and development of NDs, which may benefit the improvement of clinical treatments for these disorders and ND interventions. This review indicates existing knowledge about the involvement of microbiota present in the gut in NDs and potential treatment options. The Aging of the Enteric Nervous System https://www.fightaging.org/archives/2023/07/the-aging-of-the-enteric-nervous-system/ The enteric nervous system is the nervous system of the intestines, and likely an important part of the relationship between the gut microbiome a...
Source: Fight Aging! - July 9, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

News at a glance: China ’s ethics oversight, ARPA-H’s new science, and $210 million for protein research
PUBLIC HEALTH FDA advisers back maternal RSV shot A vaccine aims to protect infants from respiratory syncytial virus, a leading cause of infant hospitalization. JAMIE KELTER DAVIS/ THE NEW YORK TIMES /REDUX A panel advising the U.S. Food and Drug Administration (FDA) last week recommended that it approve a vaccine given to pregnant people to protect infants from respiratory syncytial virus (RSV), which can cause severe lung infections. The vote was unanimous based on the efficacy of the vaccine, called RSVpreF and branded Abrysvo. Ten members of the panel also...
Source: Science of Aging Knowledge Environment - May 25, 2023 Category: Geriatrics Source Type: research

Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news

Fight Aging! Newsletter, May 1st 2023
In conclusion, frailty progression accelerates in males with one LTCs and females with two LTCs or more. Health providers should be aware of planning a suitable intervention once the elderly have two or more health conditions. Plasma Transfer Lowers Epigenetic Age and Mortality in Rats https://www.fightaging.org/archives/2023/04/plasma-transfer-lowers-epigenetic-age-and-mortality-in-rats/ Plasma transfer from young to old individuals has produced mixed results in animals and little to no benefit in humans where assessed rigorously. These studies were driven by the hypothesis that young plasma contains me...
Source: Fight Aging! - April 30, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Measles, mumps, and rubella revaccination in children after completion of chemotherapy and hematopoietic stem cell transplantation: a single-center prospective efficacy and safety analysis
CONCLUSIONS: MMR revaccination is immunogenic for the population. We suggest periodic monitoring of antibody titers, in addition to a booster vaccination, although the optimal timing of booster vaccination remains to be investigated further.PMID:37087716 | DOI:10.1007/s12519-023-00721-x
Source: World Journal of Pediatrics : WJP - April 23, 2023 Category: Pediatrics Authors: Min Wang Qing Yuan Peng-Fei Deng Yi Fei Hua Zhang Fen Zhou Wen-Juan Chen Qing Cao Jing Chen Yi-Jin Gao Source Type: research

Gene-editing summit touts sickle cell success, while questions on embryo editing linger
After decades of living with often excruciating pain, Victoria Gray had to get used to a new sensation in recent years: waking up without it. “It may sound crazy, but I had to pinch myself to see was I still able to feel pain,” she says. Gray, a 37-year-old mother of four from Forest, Mississippi, who was born with sickle cell disease, arguably became the star of last week’s International Summit on Human Genome Editing in London when she spoke about her transformation. In 2019, she was the first person to undergo an experimental therapy in which blood stem cells were taken from her, altered with the ...
Source: Science of Aging Knowledge Environment - March 13, 2023 Category: Geriatrics Source Type: research

Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Fight Aging! Newsletter, January 16th 2023
Conclusions Implanted Hair Follicle Cells Produce Remodeling of Scar Tissue Assessment of Somatic Mosaicism as a Biomarker of Aging The Gut Microbiome of Centenarians https://www.fightaging.org/archives/2023/01/the-gut-microbiome-of-centenarians/ The state of the gut microbiome is arguably as influential on health as exercise. Various microbial species present in the gut produce beneficial metabolites, such as butyrate, or harmful metabolites, such as isoamylamine, or can provoke chronic inflammation in a variety of ways. An individual can have a better or worse microbiome, assessing these and other fu...
Source: Fight Aging! - January 15, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Eleven science stories likely to make big news in 2023
As the COVID-19 pandemic enters its fourth year as a global health emergency, researchers will continue pushing to help make the disease manageable and ordinary. They will track hundreds of subvariants of Omicron, the highly transmissible but seemingly less lethal strain of SARSCoV-2 that dominated in 2022. Virologists will watch the virus’ evolution this year to see whether it has finally slowed or a more dangerous variant pops up, evading much of the immunity that humanity has built up to previous ones. Vaccine researchers hope to develop new shots that provide broad protection against a variety of coronaviruses.  Ano...
Source: ScienceNOW - January 4, 2023 Category: Science Source Type: news

Fight Aging! Newsletter, January 2nd 2023
In conclusion, circulating monocytes in older adults exhibit increased expression of activation, adhesion, and migration markers, but decreased expression of co-inhibitory molecules. MERTK Inhibition Increases Bone Density via Increased Osteoblast Activity https://www.fightaging.org/archives/2022/12/mertk-inhibition-increases-bone-density-via-increased-osteoblast-activity/ Bone density results from the balance of constant activity on the part of osteoblasts and osteoclasts, the former building bone, the latter breaking it down. With advancing age, the balance of activity shifts to favor osteoclasts, prod...
Source: Fight Aging! - January 1, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

A Look Back at 2022: Progress Towards the Treatment of Aging as a Medical Condition
At the end of 2022, we can reflect on the fact that we are steadily entering a new era of medicine, one in which mechanisms of aging are targeted rather than ignored. It is a profound change, one that will change the shape of a human life and ultimately the human condition by eliminating the greatest sources of suffering and death in the world. Year after year, we see increased funding, ongoing progress towards therapies capable of slowing aging or reversing aspects of aging, and a growing taxonomy of such potential therapies and their target mechanisms. The view of aging in the medical community and public at large...
Source: Fight Aging! - December 30, 2022 Category: Research Authors: Reason Tags: Of Interest Source Type: blogs

Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI ™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from a cohort of the Phase 1b MajesTEC-2 study of TECVAYLI™ (teclistamab-cqyv), a first-in-class, BCMAxCD3 bispecific T-cell engager antibody, in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and lenalidomide. According to the results, the immune-based triplet therapy regimen had a manageable safety profile with no unexpected safety signals observed. A very good partial response (VGPR) or better was achieved by 90.3 percent of patients with relapsed or refractory multiple ...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients
ConclusionOur study confirms that the mRNA-1273 SARS-CoV-2 vaccine is safe in recent HCT recipients and suggests that the perceived risk of COVID-19 decreases over time.
Source: Supportive Care in Cancer - December 1, 2022 Category: Cancer & Oncology Source Type: research